Xin Lang Cai Jing·2025-10-24 01:56Core Viewpoint - Nocare Pharma's stock has shown significant volatility, with an 83.22% increase year-to-date but a recent decline in the last 5, 20, and 60 trading days [1][2] Company Overview - Nocare Pharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [1] Financial Performance - For the first half of 2025, Nocare Pharma reported revenue of 731 million yuan, a year-on-year increase of 74.26%, while the net profit attributable to shareholders was -30.09 million yuan, reflecting an 88.51% increase compared to the previous period [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 13.80% to 15,200, with an average of 0 shares per shareholder [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and E Fund Precision Medical Flexible Allocation Mixed A, with changes in their holdings indicating active investment interest [3]